{"id":30445,"date":"2024-04-11T16:18:36","date_gmt":"2024-04-11T14:18:36","guid":{"rendered":"https:\/\/www.wendelgroup.com\/?p=30445"},"modified":"2024-04-11T16:18:38","modified_gmt":"2024-04-11T14:18:38","slug":"a-new-investment-for-wendel-growth","status":"publish","type":"post","link":"https:\/\/www.wendelgroup.com\/en\/a-new-investment-for-wendel-growth\/","title":{"rendered":"A new investment for Wendel Growth"},"content":{"rendered":"<div\n    data-observer=\"item\"\n    data-animation-type=\"fade\"\n    class=\"module module-text with-margin-top- no-padding- add-bottom-padding-1 is-center-\"\n>\n    <div class=\"module-content\">\n        <div class=\"grid\">\n            <div class=\"row r-1\">\n                <div class=\"column-8\">\n                    <div class=\"text-content\">\n                        <p>In December 2023, Wendel entered into a defi- nitive agreement to acquire a minority interest in Aqemia and invested to support the company\u2019s growth. Aqemia, a French start-up specialized in pharmaceutical research using artificial intelli- gence, has developed a unique technology plat- form (the Launchpad) that combines theoretical physics and generative artificial intelligence. The technology developed by Aqemia creates medi- cation candidates that act on targets responsible for diseases not currently addressed, thereby helping to accelerate drug discovery.<\/p>\n<p>Victoire Laurenty, Principal at Wendel Growth said : &#8220;<em>The technology developed by Aqemia from fundamental research and applied to medical research is a worldwide first. We are delighted to be supportingthis team in its mission to find me- dicines faster and more effectively.&#8221;<\/em><\/p>\n\n                    <\/div>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"categories":[35],"tags":[36],"class_list":["post-30445","post","type-post","status-publish","format-standard","hentry","category-lettre-aux-actionnaires-en","tag-actualites-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.wendelgroup.com\/en\/wp-json\/wp\/v2\/posts\/30445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wendelgroup.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wendelgroup.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wendelgroup.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wendelgroup.com\/en\/wp-json\/wp\/v2\/comments?post=30445"}],"version-history":[{"count":0,"href":"https:\/\/www.wendelgroup.com\/en\/wp-json\/wp\/v2\/posts\/30445\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.wendelgroup.com\/en\/wp-json\/wp\/v2\/media?parent=30445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wendelgroup.com\/en\/wp-json\/wp\/v2\/categories?post=30445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wendelgroup.com\/en\/wp-json\/wp\/v2\/tags?post=30445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}